The recent clinical and commercial success of lipid nanoparticles (LNPs) for nucleic acid
delivery has incentivized the development of new technologies to manufacture LNPs. As …

A major challenge to advance lipid nanoparticles (LNPs) for RNA therapeutics is the
development of formulations that can be produced reliably across the various scales of drug …

Lipid nanoparticles (LNPs) for RNA and DNA delivery have attracted considerable attention
for their ability to treat a broad range of diseases and to vectorize mRNA for COVID …

Nucleic acid therapeutics hold an unprecedented promise toward treating many challenging
diseases; however, their use is hampered by delivery issues. Microfluidics, dealing with …

In the recent of years, the use of lipid nanoparticles (LNPs) for RNA delivery has gained
considerable attention, with a large number in the clinical pipeline as vaccine candidates or …

Lipid nanoparticles (LNPs) are increasingly employed to improve delivery efficiency and
therapeutic efficacy of nucleic acids. Various formulation parameters can affect the quality …

Abstract Lipid Nanoparticles (LNPs) are promising drug delivery systems for various RNAs
such as small interfering (siRNA) and messenger RNA (mRNA). Microfluidic mixing is a …

Lipid-based drug carriers have been used for clinically and commercially available delivery
systems due to their small size, biocompatibility, and high encapsulation efficiency. Use of …

Over the past decade, the therapeutic potential of nanomaterials as novel drug delivery
systems complementing conventional pharmacology has been widely acknowledged …

Microfluidic technologies are revolutionizing the synthesis of nanoscale lipid particles and
enabling new opportunities for the production of lipid-based nanomedicines. By harnessing …